Gardos pathway to sickle cell therapies?
In this issue of Blood, Ataga and colleagues report that treatment of sickle cell disease patients with senicapoc, a Gardos channel inhibitor, reduces the number of dehydrated cells, increases hemoglobin levels, and diminishes hemolysis.
Joiner
Clinton H
CH
Cincinnati Children's Hospital Medical Center, USA.